Cancer is the second leading cause of death, accounts for >200 million disability-adjusted life years worldwide. In most of countries/regions, the mortality-to-incidence ratio is distressingly high, resulting in a profound burden on public health and the economy. So, cancer research from basic to clinic has always been the focus of global medicine. As cancer research is a rapidly expanding and advancing field in recent years, a new journal Clinical Cancer Bulletin had been launched in June 2022.
Clinical Cancer Bulletin (CCB) is a strict peer-reviewed, open access, journal covering international issues relevant to clinical cancer specialists worldwide. The journal welcomes the submission of manuscripts related to clinical oncology, translational cancer research, precision oncology, and cancer prevention research.
To improve the global level of cancer prevention, benefit cancer patients, and finally win the war on cancer, we seek the original and high quality submissions related to the core area of clinical cancer research. Topics of interest include, but are not limited to, the following subjects, all in the context of clinical cancer research:
● High quality publications on clinical oncology, including surgical oncology, medical oncology, radiation oncology, chemotherapy, targeted therapy, and cancer immunotherapy;
● Innovative cancer research or translational work related to clinical oncology and precision medicine;
● Clinical trials evaluating new treatments, accompanied by research on pharmacology, and molecular alterations or biomarkers that predict response or resistance to treatment;
● High quality multidisciplinary patient care worldwide;
● Original research on cancer epidemiology and prevention;
● Global oncology education and training.
Type of articles invited:
● Research Papers
● Survey Papers
● Clinical Trials
● Review Papers
● Comparative Study
● Case Study
● Perspective
● Comments
CCB has adopted a format-free submission policy (eZ Submit). New submissions are not scrutinized for compliance with our formatting guidelines (reference style, word limits, order of components, etc.). As long as the required information is presented (cover letter, title page, abstract, references, CONSORT diagram for randomized studies, protocol for randomized and interventional trials, etc.), the manuscript will be considered by the editors.
You can submit works by the following way: E-mail the manuscript as an attached MS word file to zsccb@vip.163.com.
Journal’s website is www.clincancerbull.com, you can learn more about our journal through the website.
We are looking forward to your submission!
Editor-in-Chief
Jia FAN
Professor, Academician of Chinese Academy of Sciences
Zhongshan Hospital Affiliated to Fudan University
